Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Optimization of Hypercholesterolemia Treatment after Heart Transplant: The Role of PCSK9 Inhibitors

In Press, (this is not the final "Version of Record"). Available online 29 July, 2024
Author(s): Maria Jesus Valero-Masa, Carlos David Ortiz-Bautista, Javier Castrodeza and Manuel Martinez-Selles*
Published on: 29 July, 2024

DOI: 10.2174/0113816128315228240716183827

Price: $95

Abstract

Background: Previous studies have reported the benefit of statins after Heart Transplant (HT). However, the use of high-dose statins might be limited in some HT patients due to intolerance and interactions with immunosuppression or might not be enough to achieve Low-Density Lipoprotein (LDL) cholesterol goals. Hyperlipidemia has been associated with coronary allograft vasculopathy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors might be a safe and effective option in HT patients with suboptimal lipid control.

Methods: In a retrospective study, we identified HT patients in our center with LDL cholesterol >100 mg/dL, after diet modifications and up-titration of statins to maximum tolerated dose, treated with PCSK9i. The primary endpoint was LDL reduction one month after, and secondary endpoints were the development of donorspecific HLA antibodies (DSA) and the presence of coronary allograft vasculopathy or rejection.

Results: From January, 2018, to January, 2024, we identified five HT patients treated with PCSK9 inhibitors. In all cases, evolocumab was used. A significant reduction in LDL cholesterol was observed (151.6 ± 13.5 mg/dl to 72.4 ± 14.6 mg/dl; p = 0.04, mean reduction 75.7 ± 14.1 mg/dl), as well as in total cholesterol (231 ± 34.6 mg/dl to 152.2 ± 38.9 mg/dl; p < 0.01, mean reduction 78.8 ± 22.2 mg/dl). A significant increase in HDL cholesterol was not observed (45.4 ± 10.9 mg/dl to 46.2 ± 11.1 mg/dl; p = 0.60). One patient developed DSA five years after treatment onset. Rejection and coronary allograft vasculopathy were not observed.

Conclusion: PCSK9 inhibitors are safe and effective in reducing LDL in HT patients. However, larger studies are needed to clarify if they can reduce the development of coronary allograft vasculopathy.

[1]
Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19(6): 1315-21.
[http://dx.doi.org/10.1016/0735-1097(92)90340-S] [PMID: 1564233]
[2]
Szyguła-Jurkiewicz B, Zakliczyński M, Szczurek W, Skrzypek M, Gąsior M, Zembala M. Perioperative risk factors of cardiac allograft vasculopathy in the long-term follow-up. Transplant Proc 2016; 48(5): 1736-41.
[http://dx.doi.org/10.1016/j.transproceed.2015.10.087] [PMID: 27496482]
[3]
Noel A, Genest J. Smashing low-density lipoprotein levels and preventing coronary allograft vasculopathy: One heart transplant patient at a time. Can J Cardiol 2019; 35(1): 17-8.
[http://dx.doi.org/10.1016/j.cjca.2018.11.022] [PMID: 30595177]
[4]
Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333(10): 621-7.
[http://dx.doi.org/10.1056/NEJM199509073331003] [PMID: 7637722]
[5]
Barge-Caballero G, Barge-Caballero E, Marzoa-Rivas R, et al. Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: Short-term and long-term efficacy and safety results. Transpl Int 2015; 28(9): 1034-41.
[http://dx.doi.org/10.1111/tri.12585] [PMID: 25864881]
[6]
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[7]
Liu X, Bao X, Hu M, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature 2020; 588(7839): 693-8.
[http://dx.doi.org/10.1038/s41586-020-2911-7] [PMID: 33177715]
[8]
Xia X, Peng Z, Gu H, Wang M, Wang G, Zhang D. Regulation of PCSK9 expression and function: Mechanisms and therapeutic implications. Front Cardiovasc Med 2021; 8: 764038.
[http://dx.doi.org/10.3389/fcvm.2021.764038] [PMID: 34782856]
[9]
Ingueneau C, Hollstein T, Grenkowitz T, et al. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk. Vascul Pharmacol 2020; 135: 106804.
[http://dx.doi.org/10.1016/j.vph.2020.106804] [PMID: 32987194]
[10]
Jennings DL, Sultan L, Mingov J, et al. PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: A systematic review and meta-analysis. Heart Fail Rev 2022; 28(1): 149-56.
[http://dx.doi.org/10.1007/s10741-022-10255-5] [PMID: 35687219]
[11]
Sammour Y, Dezorzi C, Austin BA, et al. PCSK9 inhibitors in heart transplant patients: Safety, efficacy, and angiographic correlates. J Card Fail 2021; 27(7): 812-5.
[http://dx.doi.org/10.1016/j.cardfail.2021.02.018] [PMID: 33753241]
[12]
Moayedi Y, Kozuszko S, Knowles JW, et al. Safety and efficacy of PCSK9 inhibitors after heart transplantation. Can J Cardiol 2019; 35(1): 104.e1-3.
[http://dx.doi.org/10.1016/j.cjca.2018.11.004] [PMID: 30595172]
[13]
Kühl M, Binner C, Jozwiak J, et al. Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation. PLoS One 2019; 14(1): e0210373.
[http://dx.doi.org/10.1371/journal.pone.0210373] [PMID: 30650126]
[14]
Olry de Labry Lima A, Gimeno Ballester V, Sierra Sánchez JF, Matas Hoces A, González-Outón J, Alegre del Rey EJ. Cost-effectiveness and budget impact of treatment with evolocumab versus statins and ezetimibe for hypercholesterolemia in Spain. 2. Rev Esp Cardiol 2018; 71(12): 1027-35.
[http://dx.doi.org/10.1016/j.rec.2018.05.003] [PMID: 29937273]
[15]
Lekuona I. PCSK9 inhibitors: From innovation to sustainable clinical application. Rev Esp Cardiol 2018; 71(12): 996-8.
[http://dx.doi.org/10.1016/j.rec.2018.06.032] [PMID: 30150140]
[16]
Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018; 378(25): e34.
[http://dx.doi.org/10.1056/NEJMoa1800389] [PMID: 29897866]
[17]
American Diabetes Association. Lifestyle Management: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41 (Suppl. 1): S38-50.
[http://dx.doi.org/10.2337/dc18-S004] [PMID: 29222375]
[18]
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227-337.
[http://dx.doi.org/10.1093/eurheartj/ehab484] [PMID: 34458905]
[19]
Mazon-Ramos P. Del concepto de estatinas de alta potencia a los efectos extralipídicos de las estatinas. Revista Española de Cardiología Suplementos. Amsterdm: Elsevier 2015.
[20]
Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. Task force 5: Complications. J Am Coll Cardiol 1993; 22(1): 41-54.
[http://dx.doi.org/10.1016/0735-1097(93)90814-H] [PMID: 8389776]
[21]
Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43(8): 1170-80.
[http://dx.doi.org/10.1194/jlr.M100392-JLR200] [PMID: 12177161]
[22]
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379(22): 2097-107.
[http://dx.doi.org/10.1056/NEJMoa1801174] [PMID: 30403574]
[23]
Costanzo MR, Costanzo MR, Dipchand A, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29(8): 914-56.
[http://dx.doi.org/10.1016/j.healun.2010.05.034] [PMID: 20643330]
[24]
Mancini GBJ, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Can J Cardiol 2016; 32(7): S35-65.
[http://dx.doi.org/10.1016/j.cjca.2016.01.003] [PMID: 27342697]
[25]
Broch K, Gude E, Karason K, et al. Cholesterol lowering with EVOLocumab to prevent cardiac allograft vasculopathy in de-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. Clin Transplant 2020; 34(9): e13984.
[http://dx.doi.org/10.1111/ctr.13984] [PMID: 32445429]
[26]
Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9(2): 76-91.
[http://dx.doi.org/10.4330/wjc.v9.i2.76] [PMID: 28289523]
[27]
Agarwal A, Prasad GVR. Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World J Transplant 2016; 6(1): 125-34.
[http://dx.doi.org/10.5500/wjt.v6.i1.125] [PMID: 27011910]
[28]
Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: A Special Report from the American Heart Association and American College of Cardiology. Circulation 2019; 139(25): e1162-77.
[http://dx.doi.org/10.1161/CIR.0000000000000638] [PMID: 30586766]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy